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Background: In diabetes, a variety of pro-inflammatory cellular changes has been found in various cell types,
including monocytes which are known to be involved in all the phases of atherogenesis. Angiotensin II (Ang II)
type 1 receptor (AT1R) mediates the pro-atherogenic effects of Ang II whereas the type 2 receptor (AT2R) seems
associated with atheroprotection. We sought to investigate the potential changes of AT1R-AT2R expression in
human monocytes of type 2 diabetic- hypercholesterolemic patients and in hypercholesterolemic subjects, upon
clinical treatment with rosuvastatin.
Methods: The AT1R membrane protein and mRNA AT1R and AT2R expression in monocytes were investigated in 10
type 2 diabetic-hypercholesterolemic patients and in 10 hypercholesterolemic subjects, before and after 3-month
rosuvastatin treatment. Moreover, the serum cytokine levels of interferon-γ (IFN-γ) and interleukin-4 (IL-4) were
detected.
Results: As expected, rosuvastatin was associated with a change in the lipid profile in the two groups. Both the
membrane protein (P = 0.008) and the AT1R mRNA expression (P = 0.038) were significantly reduced during
treatment in the absence of AT2R expression change in diabetic-hypercholesterolemic patients whereas no
significant difference was observed in hypercholesterolemic subjects. The serum IL-4 levels were increased during
treatment whereas no change was observed in IFN-γ in diabetic-hypercholesterolemic patients. No cytokine change
was observed in hypercholesterolemic subjects.
Conclusions: Our study on monocytes of diabetic-hypercholesterolemic patients, showing a reduced AT1R but not
AT2R expression during rosuvastatin treatment, suggests that statin therapy may modulate favorably the AT1-AT2
receptor balance in subjects with coexistent type 2 diabetes.
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Results from clinical trials show that systemic markers
of inflammation correlate considerably with future
cardiovascular events, both at baseline and during
pharmacological treatments [1]. Atherosclerosis as an
immuno-inflammatory disease has been associated
with a prevalent T-helper (Th) 1 response, being
the Interferon-γ (IFN-γ) a key cytokine for pro-
inflammatory response amplification; although contro-
versial, data support an antiatherogenic effect of
Th2 responses, and Interleukin (IL)-4, the prototypic
Th2-related cytokine, is generally considered as an
anti-inflammatory cytokine [2]. The renin-angiotensin-
system has been strongly implicated in atherogenesis-
related pro-inflammatory events. Angiotensin II (Ang II)
exerts its effects through the binding of two major
receptors: the Ang II type-1 receptor (AT1R) which
mediates the majority of the pro-atherogenic well-known
Ang II actions and type-2 receptor (AT2R) that is con-
sidered counteracting the AT1R-mediated effects [3].
Recently a direct role of AT1R activation in leukocyte
and macrophages has been identified in the persistence
and/or amplification of microinflammation in vessel
walls [4,5]. Although little is known at present about the
involvement of AT2Rs in atherosclerosis, these receptors
appear to participate importantly in vascular biology
with improvement in resistance artery remodeling and
appear to be cardioprotective [6-8].
The risk of atherosclerotic cardiovascular disease is
increased 2- to 3-fold in type 2 diabetes mellitus and a
recent meta-analysis in diabetic patients further
strengthens the need of a clinical use of statins in this
patient population, irrespectively from the baseline lipid
characteristics of the patients [9]. Statins may interfere
at various levels with the inflammatory processes leading
to atherosclerosis and recent evidence, pointing to an
interaction between statins and immune function,
showed that isoprenoids could regulate T cell prolifera-
tion and Th1 differentiation [10,11]. Moreover, the
effects of statins seem to influence pathways leading to
Ang II-mediated atherosclerosis and we previously
demonstrated, in circulating neutrophils of high-
cardiovascular risk patients, interferences of treatment
on both AT1R expression and the cell membrane trans-
location Rac 1, a guanosine triphosphate–binding pro-
tein playing a key role in Ang II–operated signaling
pathways [12].
Among the circulating immune cells, monocytes are
the most studied cell subset in relation to atherosclerosis
and a key role of these cells in all the phases of athero-
genesis has been demonstrated. Monocytes are the pri-
mary immune cells that appear early on the endothelial
layer and adhere to the arterial endothelium and, after
migrating into the intima and accumulating in fattystreaks, contribute to their differentiation into macro-
phages which produce inflammatory cytokines, stimulate
smooth muscle cell proliferation and migration and pro-
duce proteolytic enzymes that render the growing plaque
more susceptible to rupture [13]. In the attempt to dis-
sect the pathophysiological aspects and causalities of
atherosclerosis and the potential effects of pharmaco-
logical treatments, it is worth focusing on cellular and
subcellular pro-atherogenetic changes associated with
atherosclerosis and their modulation by drugs. However,
most of the reported studies on the so-called pleiotropic
effects of statins have been performed in vitro or in ani-
mal models of atherosclerosis [14,15] and only very few
studies are available on cellular effects of clinically admi-
nistered statin treatment in humans. Recently a word of
caution has been raised on the basis of the notion that
the various mouse models in use for studying athero-
sclerosis differ noticeably in their response to pharmaco-
logical modifiers of atherogenesis and differences in
anatomy, lipid metabolism, and gene expression compli-
cate translation of experimental results obtained in mice
to humans [16].
Moreover, a challenge of the human cellular studies in
atherosclerosis relies on the evidence that atherosclerosis
is a highly heterogeneous condition. To minimize this
limitation of human studies, we focused on diabetic
patients who did not show clinical manifestation of ath-
erosclerosis, such as healthy subjects with pre-clinical
and early pro-atherogenous changes. We have previously
demonstrated that polymorphonuclear cells and mono-
cytes obtained from high-risk subjects express more
AT1R than monocytes from healthy donors [17-19]. In
the present study we sought to investigate whether rosu-
vastatin treatment in diabetic-hypercholesterolemic
patients could be associated with a greater modulation
of AT1R and AT2R expression in monocytes than in only
hypercholesterolemic subjects treated with rosuvastatin.
Moreover, we investigated whether the statin treatment
could interfere with Th1/Th2 profile as expressed by the
measure of serum IFN-γ and IL-4 levels.
Patients and methods
Design of the study
In 10 subjects with type 2 diabetes and hypercholesterol-
emia (DM), and in 10 hypercholesterolemic (HC) sub-
jects, monocytes were isolated from venous blood to
investigate the AT1R and AT2R expression; moreover
serum was also collected to measure cytokine produc-
tion (IFN-γ, IL-4) (see below). Patients were studied: 1]
before any pharmacological treatment and 2] after 3-
month treatment with rosuvastatin (10 mg/day; 10 PM).
The subjects were enrolled consecutively at our Lipid
Clinic (Research Center on Dyslipidemia, Clinical Medi-
cine, University of Insubria, Varese, Italy) coming from
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of dyslipidemia. As for inclusion criteria to be enrolled
in this study, no disease was found after a clinical
examination and routine laboratory tests (apart from
diabetes), and the patients did not assume any pharma-
cological treatment except for anti-diabetic treatment.
Anti-diabetic medications were allowed if the patients
were satisfactorily treated and no changes in treatment
were scheduled for the duration of the study. Eight
patients were on diet treatment, 1 assumed metformin
and 1 patient was on treatment with the association
glybenclamide/metformin. Ongoing clinical infection
and/or the presence of infections in the previous three
months as well as a smoking habitus and competitive
sporting activities were exclusion criteria. All the
patients had previously been instructed about the life-
style modification required for the treatment of their
disease, including dietary treatment (qualitative counsel-
ing) and mild physical activity. The patients were
then asked to maintain the same level of physical activ-
ity and a similar diet throughout the study. All the
patients were evaluated with a clinical visit including
familial and personal history. Among the diabetic-
hypercholesterolemic patients studied, 8 were males,
mean age was 68 ± 8 years whereas among hypercholes-
terolemic subjects mean age was 65 ± 10 years. The
body-mass-index (28.4 ± 2.7 and 27.4 ± 2.8 Kg/m2) and
waist circumference (102.6 ± 10.4 and 99 ± 10cm) were
similar respectively in diabetic and hypercholesterolemic
patients and the values did not change throughout the
study. Blood samples were obtained to perform routine
laboratory exams and to isolate circulating monocytes
for subsequent studies and to measure serum cytokines
by using heparinized tubes between 8.00 and 9.00 A.M.,
after a night of fasting. Glomerular filtration rate was
measured according to MDRD formula [20]. All the
subjects were previously asked not to take coffees, teas,
chocolates, or cola-containing substances for the 24
hours preceding the evaluations. Our study complies
with the Declaration of Helsinki; the local Ethics
Committee has approved the research protocol and
informed consent has been obtained from the subjects.
Cell isolation
Whole blood was allowed to sediment on dextran at 37°
C for 30 min. Supernatant was recovered and peripheral
blood mononuclear cells (PBMCs) were separated by
Ficoll-Paque Plus density-gradient centrifugation. A typ-
ical PBMC preparation contained about 80% lympho-
cytes and 16% monocytes, and cell viability was always
>99% as assessed by flow cytometric analysis.
Monocytes (for real-time evaluation) were further
separated from PBMCs by immunomagnetic cell sorting.
To this end, antibodies targeted to CD14 (monocytes)were obtained from Dynal A.S. (Oslo, Norway) and
added to separate aliquots of the cell suspension using a
target-to-bead ratio of 1:4 as previously described [17].Flow cytometric analysis of AT1R expression
We have evaluated the expression of AT1Rs on the cell
membrane of monocytes. To this end, 1 ml of whole
blood was used and the analysis was performed by using
conventional immunofluorescence techniques together
with a multiparametric flow cytometric analysis as previ-
ously described [17]. A minimum of 50.000 cells were
analyzed from each sample, and AT1R density on posi-
tive cells [mean fluorescence intensity (MFI)] was
obtained.RNA isolation and real-time polymerase chair reaction
(PCR) analysis of AT1R and AT2R mRNA
Total mRNA was extracted from 1x106 monocytic cells
by Perfect RNA Eukaryotic Mini kit (Eppendorf,
Hamburg, Germany) and the amount of extracted RNA
was estimated by spectrophotometry at 260 nm. Total
RNA was reverse transcribed using the high-capacity
cDNA Archive Kit (Applied Biosystems, Foster City,
USA) according to the manufacturer’s instructions.
Real-time PCR was performed by means of an ABI
prism 7000 apparatus (Applied Biosystem, Foster City,
CA) using the assay-on-demand kits (Table 1) as previ-
ously described [17,21].
Threshold cycle values (Ct1) for the genes of interest
were calculated, normalized to 18s RNA (Ct2) (house-
keeping) content and finally expressed as 2-ΔCt, where
ΔCt = Ct2 - Ct1.Measurement of serum cytokines
Serum samples collected were analysed for cytokine
content. To this end, IFN-γ, IL-4 levels in serum were
quantified using a sandwich-type enzyme-linked im-
munosorbent assay (ELISA kit; Amersham Biosciences,
UK). The detection limit of the assay was 1 pg/ml. The
control values for serum IL-4 levels were: not detectable;
and the serum control IFN-γ levels were: 0–1.5 pg/ml,
as reported for the kit used.Statistical analysis
Data are presented as mean ± standard deviation (SD). A
paired t test was used to compare variables before and
during pharmacological statin treatment. Calculations
were performed using a commercial software (GraphPad
Prism version 5.00 for Windows, GraphPad Software,
San Diego, CA, USA, www.graphpad.com) and a two-
sided P < 0.05 was retained for statistical significance.
Table 1 Real-time-Protein Chain Reaction primers
Gene name Interrogated sequence Translated protein Exon boundary Assay location IMAGE clone ID
AT1R RefSeq NM_031850.1 NP_114038.1 1-2 248 -
NM_000685.3 NP_000676.1 1-2 248 -
GeneBank mRNA S77410.1 - 1-2 201 -
BC068494.1 - 1-2 224 30337806
AT2R RefSeq NM_000686.3 NP_000677.2 2-3 129 -
GeneBank mRNA U16957.1 - 2-3 107 -
AT1R = Angiotensin II type 1 receptor; AT2R = Angiotensin II type 2 receptor.
Marino et al. Cardiovascular Diabetology 2012, 11:153 Page 4 of 7
http://www.cardiab.com/content/11/1/153Results
Lipid pattern and other laboratory characteristics were
not different at baseline in the two groups (Additional
file 1). As expected and shown in Table 2, rosuvastatin
treatment significantly affected the lipid profile of the
patients after the 3-month treatment. No change was
observed in liver and renal function. High-sensitive
serum C-reactive protein was also reduced after statin
treatment.
Flow cytometric analysis of AT1R expression
Figure 1 shows data of a representative flow cytometric
analysis of AT1R expression on monocytes of a diabetic
subject obtained before and after statin treatment (panel
A). The data shown are obtained from one represen-
tative subject. A 3-month rosuvastatin treatment
significantly reduced AT1R membrane expression in
monocytes of diabetic patients. Values (measured asTable 2 Laboratory characteristics of patients at baseline and
Diabetic patients (n = 10)
baseline treatment #
TC (mg/dl) 223.7 ± 34.0 168.5 ± 45.9 0
TG (mg/dl) 165.3 ± 73.0 118.5 ± 31.5 0
HDL-c (mg/dl) 50.0 ± 2.8 50.2 ± 6.5 0
LDL-c (mg/dl) 135.7 ± 20.6 85.0 ± 25.6 <
ApoA (mg/dl) 128.0 ± 53.0 163.0 ± 14.4 0
ApoB (mg/dl) 117.2 ± 29.1 54.0 ± 14.9 <
Glucose (mg/dl) 137.7 ± 19.4 135.5 ± 31.8 0
Insulinemia (ng/ml) 14.2 ± 3.4 16.3 ± 3.5 0
AST 24.2 ± 4.3 24.0 ± 4.1 0
ALT 37.7 ± 19.2 39.2 ± 27.1 0
GGT 43.3 ± 27.2 46.5 ± 39.6 0
CK 226.8 ±113.7 212.7 ± 103.5 0
s-creatinine 0.98 ± 0.11 0.97 ± 0.10 0
GFR 76.33 ± 12.18 77.5 ± 3.56 0
hsCRP 2.94 ± 2.02 1.76 ± 0.51 0
TC = total cholesterol; TG = triglycerides; HDL-c = high density lipoprotein-cholestero
Apolipoprotein B; AST = aspartate aminotransferase; ALT = alanine aminotransferase
filtration rate; hsCRP = high sensitivity C reactive protein. # Paired t test.MFI) observed before the institution of therapy were
1.84 ± 0.55 and reached the values of 1.17 ± 0.45 after
the clinical statin treatment (P = 0.008). Moreover in
hypercholesterolemic subjects we didn't see any differ-
ence (panel B).AT1R and AT2R mRNA expression in monocytes from
patients before and after rosuvastatin treatment
As observed for the protein expression, the mRNA ex-
pression of AT1R was significantly reduced during treat-
ment in monocytes of diabetic patients (Figure 2, panel
A) whereas no difference was observed for the AT2R
expression measured before and during statin therapy
(Figure 3, panel A).
No differences was observed for AT1R and AT2R ex-
pression measured before and during therapy in
hypercholesterolemic subjects (Figures 2 and 3, panel B).after three-month rosuvastatin therapy
Hypercholesterolemic patients (n = 10)
P baseline treatment #P
.003 288.2 ± 41.0 165.5 ± 24.4 <0.001
.012 180.9 ± 61.4 133.5 ± 58.9 0.004
.94 55.1 ± 9.9 50.7 ± 12.1 0.164
0.001 197.0 ± 34.1 88.1 ± 25.1 <0.001
.69 144.5 ± 28.5 160.1 ± 55.4 0.34
0.001 147.1 ± 38.8 75.1 ± 24.6 <0.001
.79 98.6 ± 5.7 97.0 ± 12.9 0.77
.63 18.8 ± 14.7 19.7 ± 17.0 0.63
.94 18.3 ± 5.6 17.1 ± 3.5 0.658
.78 27.6 ± 12.9 21.3 ± 4.4 0.122
.65 21.7 ± 5.9 20.1 ± 5.6 0.131
.73 135.7 ± 64.9 134.4 ± 56.6 0.994
.89 0.98 ± 0.17 0.99 ± 0.18 0.597
.79 73.22 ± 33.31 74.00 ± 12.09 0.667
.03 1.70 ± 1.69 1.15 ± 0.79 0.350
l; LDL-c = low density lipoprotein-cholesterol; ApoA = Apolipoprotein A; ApoB =
; GGT = γ-glutamyl transpeptidase; CK = creatine kinase; GFR = glomerular














Figure 1 Expression of AT1R in diabetic and
hypercholesterolemic subjects before and after 3 months of
rosuvastatin treatment. Legend: DM pts, diabetic patient; HC pts,
hypercholesterolemic patients.** P = 0,008 vs values obtained before
statin treatment.



















Figure 3 AT2R mRNA levels in monocytes of diabetic and
hypercholesterolemic subjects before and after 3 months of
rosuvastatin treatment. Legend: DM pts, diabetic patient; HC pts,
hypercholesterolemic patients.
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rosuvastatin treatment
Rosuvastatin treatment did not affect serum levels of
IFN-γ (7.97 ± 2.41 pg/ml vs 6.45 ± 3.35 pg/ml; P = 0.912).




















Figure 2 AT1R mRNA levels in monocytes of diabetic and
hypercholesterolemic subjects before and after 3 months of
rosuvastatin treatment. Legend: DM pts, diabetic patient; HC pts,
hypercholesterolemic patients. * P < 0.05 vs values obtained before
statin treatment.months of statin treatment (22.96 ± 16.53 pg/ml vs
35.10 ± 16.93 pg/ml; P = 0.020). No cytokine change was
observed in hypercholesterolemic subjects.
Discussion
The main finding of the present study is the observation
that medium-term rosuvastatin clinical treatment is
associated with reduced AT1R expression in monocytes
of type 2 diabetic patients in the absence of AT2R ex-
pression changes.
Various factors act in diabetes to induce atheroscler-
otic processes and vascular changes. Both hyperinsuline-
mia and the lipid pattern called atherogenic dyslipidemia
are well known pro-atherogenic factors [22]. Recently,
the central role of inflammation in diabetes-related ath-
erosclerosis has been underlined by the finding that pro-
inflammatory preconditioning is required for the devel-
opment of high-glucose-induced inflammation in human
aortic smooth muscle cells [23]. Moreover, altered cellu-
lar functions of various cell types have been related to
diabetes and these abnormalities may contribute to
systemic inflammation. In particular, in experimental
models of diabetes monocytes/macrophages show a
decreased phagocytosis and an increased expression of
inflammatory mediators, and cells from diabetic subjects
exhibit enhanced adherence to the endothelium [24]. As
regards the Ang II receptor expression, the functional
relevance of up-regulated AT1R expression in diabetes
has been underlined by a recent study showing that
upregulation of the ligand–Receptor for Advanced
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mechanism in diabetic atherosclerosis [25]. In diabetic
myocardium a significant increase in protein expression
and median mRNA expression of the AT1R was reported
[26]. In carotid human specimen the mRNA expression
of both angiotensinogen and angiotensin-converting en-
zyme were higher in type 2 diabetic patients than in
non-diabetic subjects whereas AT1R mRNA did not dif-
fer [27]. Previously we reported that subjects with
increased cardiovascular risk according to the Adults
Treatment Panel III guidelines had an increased
leukocyte AT1R expression at mRNA level and that this
expression was reduced during simvastatin treatment
but no study has previously focused on cellular changes
upon statin treatment in a specific diabetic population
[12,17]. In this study we did not enrolled a control group
since the comparison of the receptor expression of high
risk subjects has been already investigated [17]. More-
over, we show here for the first time that not only
mRNA, but also protein membrane expression of AT1R
was significantly reduced during rosuvastatin treatment.
AT2Rs are present in the vasculature and may induce
vasorelaxation in vivo [6-8]. Very few studies are at
present published on the AT2R expression and function-
ing in humans, and it is now generally accepted that the
AT1R blockade is associated with AT2R overexpression
and that AT2R stimulation by Ang II induces counterre-
gulatory vasodilatation that opposes AT1R–mediated
vasoconstriction [28]. Indeed, in a study on resistance
arteries dissected from gluteal subcutaneous tissues of
hypertensive diabetic patients treated with valsartan,
Ang II evoked a significant vasodilatory response which
was blocked by an AT2R inhibitor [6]. However, studies
performed on human internal mammary arteries, AT2R
receptor stimulation did not mediate vasodilation and
AT2R-mediated vasodilation in the human heart was
shown to be limited to coronary microarteries [29,30].
To our knowledge, no study is available on both AT1R
and AT2R modulation by rosuvastatin. In this study, we
show for the first time that, after treatment with rosu-
vastatin, no changes are observed in AT2R mRNA ex-
pression in monocytes of type 2 diabetic patients. This
finding strengthens the results of reduced AT1R
observed during treatment, suggesting a possible favor-
able modulation of the AT1-AT2 receptor expression
during statin treatment. Moreover, according with the
already reported finding of a relatively lower AT2R tissue
expression in the adult when compared with AT1R ex-
pression [28], we show in human monocytes of diabetic
subjects that the AT2R is expressed at a lower level than
AT1R. However we have to acknowledge that the results
reported here, obtained in a population mainly consti-
tuted by male subjects, apply only to type 2 diabetic
patients. Even if we have not recruited a control group,the reduction of AT1 receptor expression after rosuvas-
tatin treatment could be explained by a specific effect of
diabetes, given that the two groups didn’t differ in their
lipid profile. Moreover, the relatively small number of
the patients enrolled in this study or the short-term
could have influenced the results in hypercholesterole-
mic patients.
It has been recently reported that rosuvastatin was
able to affect the Th1/Th2 response in humans with
acute coronary syndrome [31]. In our study, in subjects
prone to atherosclerosis but in a stable phase of the
process as the type 2 diabetic patients studied, a signifi-
cant increase of the Th2-profile-related IL-4 was
observed whereas we did not evidence a reduction in
circulating IFN-γ during treatment. Previously, a reduc-
tion in pro-inflammatory cytokine production by circu-
lating monocytes has been associated with statin
treatment in humans [32,33]. As regards statin effects
on cytokines directly involved in immunomodulation, al-
though simvastatin-treated dendritic cells showed a Th2
transcription profile which was accompanied by
increased Th2 (IL-4, IL-5, and IL-13) and decreased Th1
(IFN-γ) cytokine secretion from the T cells [10], no lon-
gitudinal study in humans has previously shown
increased IL-4 levels during clinical statin treatment.
Other authors showed no immunomodulatory effect by
atorvastatin on the Th1/Th2 balance in human T cells
in vitro [34].
Conclusions
In conclusion, this longitudinal study in humans show
that rosuvastatin treatment is associated with reduced
monocyte AT1R but not AT2R expression, suggesting
that the clinically administered statin therapy may
modulate favorably the AT1-AT2 receptor balance in dia-
betic patients.
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Additional file 1: Laboratory characteristics of patients at baseline.
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